Evaluation of RASON Inhibitors Alone or with Standard Therapy in Patients with Advanced RAS-Mutated Non-Small Cell Lung Cancer
Led by Revolution Medicines, Inc. · Updated on 2026-10-19
616
Participants Needed
98
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of new RASON inhibitors in patients with advanced RAS-mutated non-small cell lung cancer NSCLC and other solid tumors. The study focuses on patients with specific KRAS or RAS mutations and uses an open-label platform design including multiple subprotocols to test different drug combinations and monotherapies.
Participants are assigned to one of four subprotocols testing various combinations of oral RASON inhibitorsRMC-6291, RMC-6236, and RMC-9805with or without pembrolizumab and chemotherapy. Subprotocols A, B, and C have two parts dose exploration and dose expansion, while Subprotocol D consists of one part. Treatments include oral tablets and intravenous infusions given in specific schedules, such as twice daily BID or once daily QD dosing for oral drugs and every three weeks Q3W for infusions.
Throughout the study, participants undergo regular monitoring for adverse events, dose limiting toxicities, and drug concentration levels up to 21 weeks, with antitumor responses and duration of response followed for up to five years. Safety and effectiveness assessments, including laboratory tests and clinical evaluations, are conducted during treatment and long-term follow-up to understand the drugs effects and tolerability in this patient population.
CONDITIONS
Brief Title
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Research Team
R
Revolution Medicines
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Investigational RMC‑ON regimens
What it is
Investigational oral RMC‑ON inhibitor compounds assigned in parallel molecular subprotocols (RMC‑6291 for KRAS G12C, RMC‑6236 pan‑RAS, RMC‑9805 etc.)
Role in trial
Assigned investigational treatment arms stratified by the type of RAS mutation
Primary use
Treatment of advanced or metastatic RAS‑mutated NSCLC harboring specific RAS mutations
How it is given or performed
Oral tablets given per mutation‑specific subprotocol schedule
Evidence status
Early clinical data show dose‑dependent response rates (31–37%) and median PFS around 8 months in RAS‑mutated NSCLC phase 1/2 cohort
Important risks
Safety profile under evaluation; detailed risks not yet established in NSCLC
Important limitations
No comparator arm in trial; results limited by early phase design and mutation‑specific cohorts
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
18 years of age or older
ECOG performance status of 0 or 1
Adequate organ function as required by the study
Have received prior standard therapy appropriate for tumor type and stage
Pathologically confirmed locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (Subprotocol A)
Pathologically confirmed locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
Pathologically confirmed locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocols C and D)
You will not qualify if you...
Primary central nervous system (CNS) tumors
Impaired gastrointestinal function that may significantly alter absorption of study drugs
Major surgery within 28 days before first dose
Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids
Other criteria may apply
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Varies by participant depending on dose exploration and expansion phases
Participants receive one of the study drug combinations involving oral RAS(ON) inhibitors, pembrolizumab, and possibly chemotherapy, according to their assigned subprotocol.
Regular visits for dosing and monitoring
Follow-up
Duration - Up to 5 years
Participants are monitored for adverse events, tumor response, and drug levels for up to five years after treatment.
Periodic follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.